Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Irish Pharmaceutical Healthcare Association .
Filed returns
87
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Irish Pharmaceutical Healthcare Association | Health | EU Presidency Associated event with Commission VarHelyi on European Competitiveness and the role of Life Sciences and the Pharmaceutical Industry. (Public policy or programme) | 7 | On lobbying.ie |
| May–Aug 2026 | Irish Pharmaceutical Healthcare Association | Health | Industry perspectives on access, innovation and coordination. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2026 | Irish Pharmaceutical Healthcare Association | Health | Life Sciences Strategy (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2026 | Irish Pharmaceutical Healthcare Association | Health | Number of Clinical Trials in Ireland (Public policy or programme) | 16 | On lobbying.ie |
| Jan–Apr 2026 | Irish Pharmaceutical Healthcare Association | Health | Concluding text of Framework Agreement on Pricing and Supply of Medicines 2026-2029. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Irish Pharmaceutical Healthcare Association | Health | Medicines Shortage - Provision in proposed EU General Pharmaceutical Legislation regarding medicines shortages prevention plan. (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Irish Pharmaceutical Healthcare Association | Health | Industry position on a National Life Sciences Strategy (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Irish Pharmaceutical Healthcare Association | Health | (i) IPHA priorities for EU Presidency and (ii) EU Presidency Events (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Irish Pharmaceutical Healthcare Association | Health | Moving Codeine containing OTC medicines from pharmacy only to prescription. (Public policy or programme) | 17 | On lobbying.ie |
| Sep–Dec 2025 | Irish Pharmaceutical Healthcare Association | Health | New framework Agreement on the Pricing and Supply of Medicines. (Matters involving public funds) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Irish Pharmaceutical Healthcare Association | Health | New framework Agreement on the Pricing and Supply of Medicines. (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Irish Pharmaceutical Healthcare Association | Health | US-EU Trade Tariffs (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | Future Framework Agreement (Matters involving public funds) | 3 | On lobbying.ie |
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | Self-Care Socio Economic Findings Report (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | Delays regarding the reimbursement of vaccines in Ireland. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | Number of Clinical Trials in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | Future Framework Agreement (Legislation) | 6 | On lobbying.ie |
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | Future Framework Agreement (Legislation) | 3 | On lobbying.ie |
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | Future Framework Agreement - issues concerning timely reimbursement of medicines in Ireland. (Public policy or programme) | 10 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on access to medicines in EU smaller countries/markets and intellectual property rights. (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revisions of EU General Pharmaceutical Legislation and (ii) Irish Government Position on intellectual property rights. (Legislation) | 2 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on intellectual property rights. (ii) Issues concerning the timely reimbursement of medicines in Ireland. (iii) Industry… (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Electronic Health Records for a property functioning health system. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Electronic Health Records for a property functioning health system. (Matters involving public funds) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on intellectual property rights. (ii) Issues concerning the timely reimbursement of medicines in Ireland. (iii) Industry… (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revisions of EU General Pharmaceutical Legislation and (ii) Irish Government Position on intellectual property rights. (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Issues concerning the timely reimbursement of medicines in Ireland. (Public policy or programme) | 12 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | European Commission Urban Waste Water Treatment Directive, with particular attention to the polluter payers and principal and proportional responsibility. (Legislation) | 2 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) New Supply Agreement; (ii) Access to new medicines. (Matters involving public funds) | 3 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | EU Commission proposed revision of the EU General Pharmaceutical Legislation and related matters, with particular attention to intellectual property rights provisions, competitiveness and regulatory affairs. (Legislation) | 8 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | Issues concerning the timely reimbursement of medicines in Ireland. (Public policy or programme) | 13 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | European Commission Urban Waste Water Treatment Directive (UWWTD), with particular attention to the polluter payers principal and proportional responsibility. (Legislation) | 8 | On lobbying.ie |
| May–Aug 2024 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revision of EU General Pharmaceutical Legislation, particularly items relating to incentives/intellectual property rights; (ii) EU wide access to new medicines. (Legislation) | 10 | On lobbying.ie |
| Jan–Apr 2024 | Irish Pharmaceutical Healthcare Association | Health | (1) Budget 2024 - the need for funding of new medicines. (2) Likely no provision for new developments funding to HSE for new medicines in Budget 2024. (3) Absence of funding for new medicines in Budget 2024. (4)… (Matters involving public funds) | 34 | On lobbying.ie |
| Sep–Dec 2023 | Irish Pharmaceutical Healthcare Association | Health | (1) Reimbursement process improvements under consideration in the Mazar's Working Group. (2) Delays within Medicines Reimbursement System. (3) Preparation for negotiation of a Framework Agreement in 2025. (4) Process… (Public policy or programme) | 16 | On lobbying.ie |
| Sep–Dec 2023 | Irish Pharmaceutical Healthcare Association | Health | Review of EU Council and Parliament process for proposed amendments to pharmaceutical legislation. (Legislation) | 2 | On lobbying.ie |
| May–Aug 2023 | Irish Pharmaceutical Healthcare Association | Health | Budget 2024 - Exchequer allocation to HSE for new medicines expenditure in 2024. (Matters involving public funds) | 3 | On lobbying.ie |
| May–Aug 2023 | Irish Pharmaceutical Healthcare Association | Health | Matters under consideration that the European EPSCO Council in June, including the proposed revision of the General Pharmaceutical Legislation. (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Irish Pharmaceutical Healthcare Association | Health | Reimbursement processes under the 2013 Health Act; - IPHA draft proposals (Matters involving public funds) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Irish Pharmaceutical Healthcare Association | Health | Revision of pharmaceutical legislation by European Commission. (Legislation) | 10 | On lobbying.ie |
| Sep–Dec 2022 | Irish Pharmaceutical Healthcare Association | Health | Congratulations on appointment. Seek support for fast access to new medicines and for innovation in the EU Pharmaceutical Strategy. (Public policy or programme) | 6 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | EU Pharmaceutical Strategy (Public policy or programme) | 13 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | Discussion on EU pharmaceutical strategy and other matters. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | Budget submission (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | Support for innovation and IP in forthcoming EU Pharmaceutical Strategy (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | Gas supplies and pharmaceutical production. (Legislation) | 4 | On lobbying.ie |
| Jan–Apr 2022 | Irish Pharmaceutical Healthcare Association | Health | (i) EU Pharmaceutical Policy; (ii) EFPIA WAIT Indicator Survey - Access to new medicines; (iii) Access to Orphan Medicines; (iv) EU Pharmaceutical Strategy (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2021 | Irish Pharmaceutical Healthcare Association | Health | Preparation for a meeting, management of negotiations, of a new framework agreement on the pricing and supply of medicines. (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2021 | Irish Pharmaceutical Healthcare Association | Health | Negotiations on a new framework agreement on supply and pricing of medicines. (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2021 | Irish Pharmaceutical Healthcare Association | Health | WTO TRIPS Waiver of IP rights (Public policy or programme) | 4 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 86 | 98.9% | |
| Budgetary matters | 1 | 1.1% |